Last updated: February 19, 2026

FULVICIN P/G 165, a griseofulvin-based antifungal medication, targets dermatophytosis, commonly known as ringworm. The drug's market trajectory is influenced by patent expirations, generic competition, and evolving treatment guidelines for fungal infections.

What is the Current Patent Landscape for FULVICIN P/G 165?

The primary patent for FULVICIN P/G 165 has expired. Original patents, such as U.S. Patent 4,145,442, covering the composition and method of treatment using griseofulvin, were granted in the late 1970s and have long since lapsed. This lack of market exclusivity for the parent compound allows for broad generic market entry.

The pharmaceutical market for griseofulvin-based products, including FULVICIN P/G 165, operates under a post-patent expiration model. This means competition is primarily driven by manufacturing efficiency, cost of goods, and distribution networks rather than novel intellectual property protection for the active pharmaceutical ingredient itself.

While the core griseofulvin patents are expired, any new formulations, delivery systems, or combination therapies involving griseofulvin could potentially be subject to new patent filings. However, for the established FULVICIN P/G 165 product as a singular entity, the patent protection is no longer a primary market barrier.

Who are the Key Manufacturers and Competitors?

The market for griseofulvin, including products marketed as FULVICIN P/G 165, is characterized by the presence of multiple generic manufacturers. The original brand name holder is no longer the sole supplier, and the market has fragmented.

Key competitors in the griseofulvin market include companies that manufacture and distribute generic versions of oral griseofulvin. These include:

Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.): Historically a significant player with brand names such as GRIS-PEG.
Teva Pharmaceutical Industries Ltd.
Mylan N.V. (now Viatris Inc.)
Impax Laboratories, Inc. (now Amneal Pharmaceuticals LLC)
Numerous other regional and international generic drug manufacturers.

These companies compete based on pricing, product availability, and market penetration. The existence of multiple generic suppliers intensifies price competition, directly impacting the revenue potential for any single product formulation.

What is the Current Market Size and Projected Growth for Oral Antifungals?

The market for oral antifungal medications, encompassing griseofulvin and its alternatives, is substantial and exhibits steady growth. The specific market size for griseofulvin alone is difficult to isolate due to its classification within broader antifungal drug categories.

Global oral antifungal drug market size was valued at approximately USD 13.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 4.5% from 2023 to 2030 [1]. This growth is driven by:

Increasing prevalence of fungal infections: Factors contributing include rising immunocompromised populations (e.g., due to HIV/AIDS, chemotherapy, organ transplantation) and increasing incidences of dermatological conditions.
Advancements in drug discovery and development: While griseofulvin is an older drug, research continues into new antifungal agents and improved delivery mechanisms.
Growing awareness and diagnosis: Improved diagnostic tools and increased patient and physician awareness lead to higher identification and treatment rates.

Griseofulvin occupies a niche within this market, primarily for dermatophytosis of the skin and hair. Its market share is influenced by the availability and efficacy of alternative treatments.

How Do Treatment Guidelines Affect Griseofulvin Usage?

Treatment guidelines from organizations like the Infectious Diseases Society of America (IDSA) and the American Academy of Dermatology (AAD) influence the prescribing patterns for oral antifungals. Griseofulvin is often recommended as a first-line or alternative treatment for specific types of fungal infections.

Current guidelines generally position griseofulvin for:

Tinea Capitis (scalp ringworm): Especially those caused by Microsporum species. While effective, it often requires prolonged treatment courses.
Tinea Corporis and Tinea Cruris (body and groin ringworm): Less commonly used for these conditions compared to topical treatments unless infections are extensive or unresponsive to topical therapy.
Tinea Pedis and Tinea Manuum (athlete's foot and hand ringworm): Typically considered when topical treatments fail or infections are severe.

Factors influencing guideline recommendations and thus griseofulvin usage include:

Efficacy against specific pathogens: Griseofulvin demonstrates good activity against dermatophytes but has limited spectrum against other fungal types.
Safety profile and side effects: Potential side effects include gastrointestinal upset, headache, and photosensitivity. Drug-drug interactions also need consideration.
Cost-effectiveness: As a generic medication, griseofulvin generally offers a cost-effective treatment option, particularly in resource-limited settings.
Availability of newer agents: The development of more potent, broader-spectrum antifungals (e.g., terbinafine, itraconazole, fluconazole) has led to a shift in prescribing practices for certain indications where these newer agents may offer improved efficacy or shorter treatment durations.

The prolonged treatment duration often associated with griseofulvin (typically 4-12 weeks) can impact patient adherence, a factor that influences its competitive standing against shorter-course alternatives.

What is the Pricing and Reimbursement Landscape?

The pricing of FULVICIN P/G 165 is characteristic of a mature generic drug. Prices are highly competitive, driven by multiple manufacturers vying for market share.

Wholesale Acquisition Cost (WAC): WAC for generic griseofulvin tablets (e.g., 500 mg) can range from approximately $0.10 to $0.50 per tablet, depending on the manufacturer, quantity, and distributor. This translates to a total treatment cost that is generally low.
Reimbursement: Griseofulvin is widely covered by most major public and private health insurance plans in markets like the United States. Reimbursement rates are set based on average wholesale prices (AWP) or other negotiated fee schedules. Generic status ensures it is typically reimbursed at lower levels than branded or newer medications.
Out-of-Pocket Costs: For patients with co-pays or high-deductible plans, out-of-pocket costs for a course of griseofulvin treatment are generally minimal, often ranging from a few dollars to under $20.

The low price point means that profitability for manufacturers relies on high-volume sales and efficient manufacturing processes. For a product like FULVICIN P/G 165, its financial trajectory is less about price increases and more about market share maintenance and cost control.

What are the Key Economic Drivers and Challenges?

The economic drivers for FULVICIN P/G 165 are rooted in its established efficacy, low cost, and broad availability as a generic medication.

Key Economic Drivers:

Cost-Effectiveness: Griseofulvin remains one of the most affordable oral antifungal options for treating dermatophytosis, making it a preferred choice in price-sensitive markets and for large-scale public health programs.
Established Treatment Protocol: Its long history of use means that healthcare providers are familiar with its dosing, efficacy, and side effect profile.
Addressing Specific Indications: It continues to be a recommended option for certain types of tinea capitis where alternatives may be more expensive or less effective for specific pathogens.
Global Accessibility: Its generic nature facilitates widespread manufacturing and distribution, ensuring accessibility in diverse healthcare systems worldwide.

Key Economic Challenges:

Intense Generic Competition: The market is crowded with numerous generic manufacturers, leading to significant price erosion and thin profit margins.
Competition from Newer Antifungals: The availability of newer oral antifungals with potentially broader spectrums of activity, shorter treatment durations, and improved safety profiles (e.g., terbinafine) can limit griseofulvin's market share for certain indications.
Long Treatment Durations: The need for extended treatment courses (often weeks to months) can lead to lower patient adherence, potentially impacting treatment outcomes and reducing overall demand for extended therapy.
Limited Innovation: As an older drug without patent protection, there is little incentive for significant R&D investment in new formulations or delivery systems for griseofulvin itself. Any innovation would likely come from third-party repackaging or combination therapies.
Regulatory Hurdles for New Entrants: While the drug is off-patent, establishing new manufacturing facilities or obtaining regulatory approvals in different markets still involves significant investment and time.

The financial trajectory of FULVICIN P/G 165 is therefore one of stable, albeit low-margin, revenue generation driven by consistent demand for cost-effective antifungal treatment, counterbalanced by constant pressure from generic competitors and the emergence of alternative therapies.

What is the Future Outlook for FULVICIN P/G 165?

The future outlook for FULVICIN P/G 165 is one of continued relevance as a cost-effective treatment option for specific dermatophytosis, rather than one of significant growth or market expansion.

Sustained Niche Market: Griseofulvin will likely maintain its position as a go-to treatment for certain types of tinea capitis, particularly in regions where cost is a primary consideration or where specific pathogen profiles favor its use.
Price Sensitivity: The market will remain highly price-sensitive. Profitability will depend on manufacturers' ability to achieve economies of scale and optimize production costs.
Competition Dynamics: The competitive landscape will continue to be dominated by generic manufacturers. Market share will fluctuate based on pricing strategies and supply chain reliability.
Impact of Guidelines: Any shifts in clinical treatment guidelines that favor alternative therapies could negatively impact demand. Conversely, guidelines that maintain griseofulvin's role for specific indications will support its market position.
Limited Innovation Potential: Significant R&D investment into the FULVICIN P/G 165 formulation itself is unlikely. Future developments might involve novel combination therapies or delivery methods, but these would likely fall outside the scope of the core product's financial trajectory.

Overall, FULVICIN P/G 165 is expected to remain a stable, albeit low-growth, product within the oral antifungal market. Its financial success is tied to its established role as an affordable and accessible treatment for specific fungal infections, rather than any novel market opportunities.

Key Takeaways

FULVICIN P/G 165, an oral griseofulvin antifungal, operates in a post-patent expiration market with significant generic competition.
The global oral antifungal market is projected to grow at approximately 4.5% CAGR, driven by increasing fungal infection prevalence.
Treatment guidelines position griseofulvin for specific dermatophytosis, particularly tinea capitis, but newer agents offer alternatives.
Pricing is highly competitive, with low generic costs and widespread insurance reimbursement, emphasizing volume over margin.
The future outlook is for sustained niche market presence as a cost-effective option, with profitability dependent on manufacturing efficiency and cost control.

Frequently Asked Questions

Are there any active patents protecting FULVICIN P/G 165 that would prevent generic entry? No, the primary patents covering the griseofulvin compound and its basic use have long expired, allowing for broad generic market entry.
What are the primary indications for which FULVICIN P/G 165 is still recommended? Griseofulvin, including formulations like FULVICIN P/G 165, is primarily recommended for tinea capitis (scalp ringworm), especially in cases caused by Microsporum species. It can also be used for extensive or unresponsive cases of tinea corporis.
How does the cost of FULVICIN P/G 165 compare to newer oral antifungal medications? FULVICIN P/G 165 is significantly more cost-effective than newer oral antifungals such as terbinafine or itraconazole, which often carry higher price points due to development costs and market positioning.
What are the main side effects associated with FULVICIN P/G 165? Common side effects include gastrointestinal upset (nausea, vomiting, diarrhea), headache, dizziness, and photosensitivity (increased sensitivity to sunlight). Drug interactions are also a consideration.
What is the typical duration of treatment for fungal infections treated with FULVICIN P/G 165? Treatment courses for griseofulvin are typically prolonged, often ranging from 4 to 12 weeks, depending on the site and severity of the infection, and the specific fungal pathogen involved.

Cited Sources

[1] Grand View Research. (2023). Oral Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes), By Application (Dermatophytosis, Candidiasis, Aspergillosis), By End-use, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/oral-antifungal-drugs-market

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	76
Patent Applications:	4,486
DailyMed Link:	FULVICIN P/G 165 at DailyMed

Drug Class	Tubulin Inhibiting Agent
Physiological Effect	Decreased Mitosis Microtubule Inhibition

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	FULVICIN P/G 165	griseofulvin, ultramicrosize	TABLET;ORAL	061996-003	Apr 6, 1982		RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

FULVICIN P/G 165 Drug Patent Profile

Which patents cover Fulvicin P/g 165, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fulvicin P/g 165

AI Deep Research

Questions you can ask:

Summary for FULVICIN P/G 165

Pharmacology for FULVICIN P/G 165

US Patents and Regulatory Information for FULVICIN P/G 165

FULVICIN P/G 165: Market Dynamics and Financial Trajectory